Esperion Therapeutics | ESPR - Debt


Esperion Therapeutics reported $262.92M in Debt for its fiscal quarter ending in September of 2024.





Debt Change Date
AbbVie USD 1000K 70.48B Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Alterity Therapeutics Limited AUD 210.39K 120.67K Jun/2023
Amarin USD 0 0 Mar/2025
Amgen USD 54.59B 1.62B Sep/2025
Biogen USD 6.29B 1.7M Dec/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Cipla INR 4.38B 231.9M Mar/2025
CSL USD 11.96B 219M Dec/2024
Cytokinetics USD 1.2B 338.79M Sep/2025
Daiichi Sankyo JPY 201.14B 99.81B Sep/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Geron USD 121.92M 73K Sep/2025
Grifols EUR 9.23B 626.05M Dec/2024
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Merck USD 41.37B 5.97B Sep/2025
Minerva Neurosciences USD 0 0 Sep/2024
Moderna USD 734M 7M Sep/2025
Nektar Therapeutics USD 0 0 Jun/2022
Pfizer USD 60.85B 78M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Regeneron Pharmaceuticals USD 2.71B 400K Sep/2025
Sanofi EUR 21.76B 530M Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024